PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14663984

Web and mobile secure access to a Web based medical system.

Vasileios Skilogiannis·Themis Panayiotopoulos·Stavros Papadakis·Virginia Grammenou·Ioannis Mantas
View original source ↗Export metadata ↓

Abstract

This paper describes the implementation of the Web Based Pneumonia Chemotherapeutics (WPCh) a Web-based expert system for chemotherapeutic assistantship for nosocomial and community-acquired pneumonia based on different types of data. WPCh can be accessed through World Wide Web or a mobile phone using the relevant script languages. The core of the paper focuses on the usage of security of data and the procedures used to accomplish this task. After the log in of the physician, he can take advantage of the various modules of the expert system in order to view chemotherapeutics and save the data that he prefers. The whole procedure can be followed through the interfaces of wap technology.

Explore related subjects

Community-Acquired InfectionsComputer SecurityCross InfectionExpert SystemsGreeceHumansInternetPneumoniaProfessional-Patient RelationsUser-Computer InterfaceJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Vasileios Skilogiannis, Themis Panayiotopoulos, Stavros Papadakis, Virginia Grammenou, Ioannis Mantas. 2003. Web and mobile secure access to a Web based medical system.. https://pubmed.ncbi.nlm.nih.gov/14663984/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

CTX-M: changing the face of ESBLs in Europe.

Since around 2000 - earlier in Poland and Spain and later in France and the UK - dramatic shifts have occurred in the prevalence and types of extended-spectrum beta-lactamases (ESBLs) in Europe. Before this watershed, most producers were nosocomial isolates, often Klebsiella spp. or Enterobacter spp. from specialist care units, and had mutant TEM or SHV ESBLs. Subsequently, CTX-M ESBLs have become dominant, with much greater penetration into Escherichia coli, and with many infections in 'complicated community' patients, usually with underlying disease, recent antibiotic usage, or healthcare contact. The degree of clonality among producers varies with the country, as does the enzyme type produced, with group 9 (CTX-M-9 and -14) enzymes dominant in Spain and group 1 enzymes (particularly CTX-M-3 and -15) dominant elsewhere. Irrespective of the particular enzyme, most producers are multiresistant. These changing patterns present major therapeutic and infection control challenges, with the public health intervention points unclear.

Community-Acquired Infections↗